Document is current
Any future updates will be listed below
-
Authors
Williams, David M. https://orcid.org/0000-0001-9206-5837
Alberts, Barbara-Alex
Sharaf, Asem
Sharaf, Giselle
Bain, Stephen C.
Kalhan, Atul
Min, Thinzar
- License Information
-
More Information
Article History
Received: 19 February 2024
Accepted: 16 April 2024
First Online: 9 May 2024
Declarations
:
: David M Williams received honoraria from AstraZeneca unrelated to this work. Stephen Bain received grants, teaching sponsorship and honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk A/S, Pfizer, Sanofi, and Takeda unrelated to this work. Stephen Bain is an Editorial Board member of Diabetes Therapy. Stephen Bain was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Thinzar Min has received honoraria from Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, and Napp unrelated to this work. Barbara-Alex Alberts, Asem Sharaf, Giselle Sharaf, and Atul Kalhan have no competing interests to declare.
: This analysis was conducted as part of a service-based evaluation project to examine the effects of semaglutide therapy, which is routine in our local practice following the introduction of new diabetes therapies. Data were collected retrospectively, unidentified for the analysis and are presented anonymously. Therefore, ethical approval was not required.
